melphalan flufenamide
Selected indexed studies
- Melphalan Flufenamide (Melflufen): First Approval. (Drugs, 2021) [PMID:33961277]
- Melphalan flufenamide for relapsed/refractory multiple myeloma. (Drugs Today (Barc), 2022) [PMID:35983927]
- ** (, 2024) [PMID:40127320]
_Worker-drafted node — pending editorial review._
Connections
melphalan flufenamide is a side effect of
Sources
- Melphalan Flufenamide (Melflufen): First Approval. (2021) pubmed
- Melphalan flufenamide for relapsed/refractory multiple myeloma. (2022) pubmed
- PMID:40127320 (2024) pubmed
- Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma. (2021) pubmed
- Optimizing the use of melflufen (melphalan flufenamide) in relapsed or refractory multiple myeloma: recommendations for clinical practice. (2025) pubmed
- Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes. (2021) pubmed
- The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA. (2022) pubmed
- Melphalan-flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma. (2016) pubmed
- Autopsy of a Drug Withdrawal - The Case of Melphalan Flufenamide. (2024) pubmed
- Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide. (2020) pubmed